Functional selectivity and classical concepts of quantitative pharmacology

Journal of Pharmacology and Experimental Therapeutics

Volumn 320, Issue 1, 2007, Pages 1-13

  Urban, Jonathan D ^a   Clarke, William P ^c   Von Zastrow, Mark ^d   Nichols, David E ^e   Kobilka, Brian ^f   Weinstein, Harel ^g   Javitch, Jonathan A ^h   Roth, Bryan L ^b   Christopoulos, Arthur ⁱ   Sexton, Patrick M ⁱ   Miller, Keith J ^j   Spedding, Michael ^k   Mailman, Richard B ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c University of California ^*  (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e PURDUE UNIVERSITY   (United States)

^f STANFORD UNIVERSITY   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

^h The New York Presbyterian Hospital   (United States)

ⁱ MONASH UNIVERSITY   (Australia)

^j BRISTOL MYERS SQUIBB   (United States)

^k INSTITUT DE RECHERCHES SERVIER   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

1 (3 TRIFLUOROMETHYLPHENYL)PIPERAZINE; 6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BUFOTENINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; G PROTEIN COUPLED RECEPTOR; LIGAND; LYSERGIDE; MU OPIATE RECEPTOR; OPIATE; QUIPAZINE; SEROTONIN; SEROTONIN 2 ANTAGONIST; SEROTONIN 2A AGONIST; VASOPRESSIN; VASOPRESSIN V2 RECEPTOR;

CLINICAL PHARMACOLOGY; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG MECHANISM; HUMAN; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; LIGANDS; PROTEIN CONFORMATION; RECEPTORS, ADRENERGIC, BETA-2; RECEPTORS, CELL SURFACE; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, OPIOID, MU; RECEPTORS, VASOPRESSIN; SIGNAL TRANSDUCTION;

EID: 33845903110     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.104463     Document Type: Review

References (113)

1. Alvarez VA, Arttamangkul S, Dang V, Salem A, Whistler JL, von Zastrow M, Grandy DK, and Williams JT (2002) mu-Opioid receptors: ligand-dependent activation of potassium conductance, desensitization, and internalization. J Neurosci 22:5769-5776.
2. Anji A, Kumari M, Sullivan Hanley NR, Bryan GL, and Hensler JG (2000) Regulation of 5-HT(2A) receptor mRNA levels and binding sites in rat frontal cortex by the agonist DOI and the antagonist mianserin. Neuropharmacology 39:1996-2005.
3. Ariens EJ (1954) Affinity and intrinsic activity in the theory of competitive inhibition. I. Problems and theory. Arch Int Pharmacodyn Ther 99:32-49.
4. Baneres JL and Parello J (2003) Structure-based analysis of GPCR function: evidence for a novel pentameric assembly between the dimeric leukotriene B4 receptor BLT1 and the G-protein. J Mol Biol 329:815-829.
5. Barak LS, Oakley RH, Laporte SA, and Caron MG (2001) Constitutive arrestinmediated desensitization of a human vasopressin receptor mutant associated with nephrogenic diabetes insipidus. Proc Natl Acad Sci USA 98:93-98.
6. Baranski TJ, Herzmark P, Lichtarge O, Gerber BO, Trueheart J, Meng EC, Iiri T, Sheikh SP, and Bourne HR (1999) C5a receptor activation. Genetic identification of critical residues in four transmembrane helices. J Biol Chem 274:15757-15765.
7. Benovic JL, Staniszewski C, Mayor F Jr, Caron MG, and Lefkowitz RJ (1988) beta-Adrenergic receptor kinase. Activity of partial agonists for stimulation of adenylate cyclase correlates with ability to promote receptor phosphorylation. J Biol Chem 263:3893-3897.
8. Berg KA, Cropper JD, Niswender CM, Sanders-Bush E, Emeson RB, and Clarke WP (2001) RNA-editing of the 5-HT(2C) receptor alters agonist-receptor-effector coupling specificity. Br J Pharmacol 134:386-392.
9. Berg KA, Maayani S, Goldfarb J, and Clarke WP (1998a) Pleiotropic behavior of 5-HT2A and 5-HT2C receptor agonists. Ann NY Acad Sci 861:104-110.
10. Berg KA, Maayani S, Goldfarb J, Scaramellini C, Leff P, and Clarke WP (1998b) Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol Pharmacol 54:94-104.
11. Berry SA, Shah MC, Khan N, and Roth BL (1996) Rapid agonist-induced internalization of the 5-hydroxytryptamine2A receptor occurs via the endosome pathway in vitro. Mol Pharmacol 50:306-313.
12. 2A receptors during endocytosis. J Biol Chem 276:8269-8277.
13. Brewster WK, Nichols DE, Riggs RM, Mottola DM, Lovenberg TW, Lewis MH, and Mailman RB (1990) trans-10,11-Dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a-] phenanthridine: a highly potent selective dopamine D1 full agonist. J Med Chem 33:1756-1764.
14. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, and Molinoff PB (2002) Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302:381-389.
15. Campagne F, Neves S, Chang CW, Skrabanek L, Ram PT, Iyengar R, and Weinstein H (2004) Quantitative information management for the biochemical computation of cellular networks. Sci STKE 2004:l11.
16. Charifson PS, Bowen JP, Wyrick SD, Hoffman AJ, Cory M, McPhail AT, and Mailman RB (1989) Conformational analysis and molecular modeling of 1-phenyl-, 4-phenyl-, and 1-benzyl-1,2,3,4-tetrahydroisoquinolines as D1 dopamine receptor ligands. J Med Chem 32:2050-2058.
17. Christopoulos A and Kenakin T (2002) G protein-coupled receptor allosterism and complexing. Pharmacol Rev 54:323-374.
18. Christopoulos A, Parsons AM, Lew MJ, and El Fakahany EE (1999) The assessment of antagonist potency under conditions of transient response kinetics. Eur J Pharmacol 382:217-227.
19. Clarke WP and Bond RA (1998) The elusive nature of intrinsic efficacy. Trends Pharmacol Sci 19:270-276.
20. Cosi C, Carilla-Durand E, Assie MB, Ormiere AM, Maraval M, Leduc N, and Newman-Tancredi A (2006) Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release. Eur J Pharmacol 535:135-144.
21. q/11 and Gi(3) proteins at 5-hydroxytryptamine(2C) receptors revealed by antibody capture assays: influence of receptor reserve and relationship to agonist-directed trafficking. Mol Pharmacol 62:578-589.
22. Davies A, Gowen BE, Krebs AM, Schertler GF, and Saibil HR (2001) Three-dimensional structure of an invertebrate rhodopsin and basis for ordered alignment in the photoreceptor membrane. J Mol Biol 314:455-463.
23. De Deurwaerdere P, Navailles S, Berg KA, Clarke WP, and Spampinato U (2004) Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens. J Neurosci 24:3235-3241.
24. 2A receptor determines relative efficacy. Mol Pharmacol 63:36-43.
25. Elphick GF, Querbes W, Jordan JA, Gee GV, Eash S, Manley K, Dugan A, Stanifer M, Bhatnagar A, Kroeze WK, et al. (2004) The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science (Wash DC) 306:1380-1383.
26. Engelhardt B and Briskin MJ (2005) Therapeutic targeting of alpha 4-integrins in chronic inflammatory diseases: tipping the scales of risk towards benefit? Eur J Immunol 35:2268-2273.
27. Felder CC, Kanterman RY, Ma AL, and Axelrod J (1990) Serotonin stimulates phospholipase A2 and the release of arachidonic acid in hippocampal neurons by a type 2 serotonin receptor that is independent of inositol phospholipid hydrolysis. Proc Natl Acad Sci USA 87:2187-2191.
28. Feldman BJ, Rosenthal SM, Vargas GA, Fenwick RG, Huang EA, Matsuda-Abedini M, Lustig RH, Mathias RS, Portale AA, Miller WL, et al. (2005) Nephrogenic syndrome of inappropriate antidiuresis. N Engl J Med 352:1884-1890.
29. Filipek S, Krzysko KA, Fotiadis D, Liang Y, Saperstein DA, Engel A, and Palczewski K (2004) A concept for G protein activation by G protein-coupled receptor dimers: the transducin/rhodopsin interface. Photochem Photobiol Sci 3:628-638.
30. Filizola M and Weinstein H (2005) The structure and dynamics of GPCR oligomers: a new focus in models of cell-signaling mechanisms and drug design. Curr Opin Drug Discov Devel 8:577-584.
31. Furchgott RF (1966) The use of -haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor-agonist complexes, in Adv Drug Res (Harper NJ and Simmonds AB eds) Vol. 3, pp 21-55, Academic Press, New York.
32. Gay EA, Urban JD, Nichols DE, Oxford GS, and Mailman RB (2004) Functional selectivity of D2 receptor ligands in a Chinese hamster ovary hD2L cell line: evidence for induction of ligand-specific receptor states. Mol Pharmacol 66:97-105.
33. Gether U, Lin S, Ghanouni P, Ballesteros JA, Weinstein H, and Kobilka BK (1997) Agonists induce conformational changes in transmembrane domains III and VI of the beta2 adrenoceptor. EMBO (Eur Mol Biol Organ) J 16:6737-6747.
34. Ghanouni P, Gryczynski Z, Steenhuis JJ, Lee TW, Farrens DL, Lakowicz JR, and Kobilka BK (2001) Functionally different agonists induce distinct conformations in the G protein coupling domain of the β2 adrenergic receptor. J Biol Chem 276:24433-24436.
35. Gonzalez-Maeso J, Yuen T, Ebersole BJ, Wurmbach E, Lira A, Zhou M, Weisstaub N, Hen R, Gingrich JA, and Sealfon SC (2003) Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex. J Neurosci 23:8836-8843.
36. Gray JA and Roth BL (2001) Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists. Brain Res Bull 56:441-451.
37. Gronemeyer H, Gustafsson JA, and Laudet V (2004) Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Discov 3:950-964.
38. Guo W, Shi L, Filizola M, Weinstein H, and Javitch JA (2005) Crosstalk in G protein-coupled receptors: changes at the transmembrane homodimer interface determine activation. Proc Natl Acad Sci USA 102:17495-17500.
39. Hanley NR and Hensler JG (2002) Mechanisms of ligand-induced desensitization of the 5-hydroxytryptamine(2A) receptor. J Pharmacol Exp Ther 300:468-477.
40. Hausdorff WP, Campbell PT, Ostrowski J, Yu SS, Caron MG, and Lefkowitz RJ (1991) A small region of the beta-adrenergic receptor is selectively involved in its rapid regulation. Proc Natl Acad Sci USA 88:2979-2983.
41. He L, Fong J, von ZM, and Whistler JL (2002) Regulation of opioid receptor trafficking and morphine tolerance by receptor oligomerization. Cell 108:271-282.
42. Hess EJ, Norman AB, and Creese I (1988) Chronic treatment with dopamine receptor antagonists: behavioral and pharmacologic effects on D1 and D2 dopamine receptors. J Neurosci 8:2361-2370.
43. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR, and Humphrey PP (1994) International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 46:157-203.
44. Jim KF, Macia RA, and Matthews WD (1985) An evaluation of the ability of a series of full alpha-1 adrenoceptor agonists to release internal calcium in venous smooth muscle. J Pharmacol Exp Ther 235:377-381.
45. Keith DE, Anton B, Murray SR, Zaki PA, Chu PC, Lissin DV, Monteillet-Agius G, Stewart PL, Evans CJ, and von Zastrow M (1998) mu-Opioid receptor internalization: opiate drugs have differential effects on a conserved endocytic mechanism in vitro and in the mammalian brain. Mol Pharmacol 53:377-384.
46. Keith DE, Murray SR, Zaki PA, Chu PC, Lissin DV, Kang L, Evans CJ, and von ZM (1996) Morphine activates opioid receptors without causing their rapid internalization. J Biol Chem 271:19021-19024.
47. Kenakin T (1995) Pharmacological proteus? Trends Pharmacol Sci 16:256-258.
48. Kenakin T (1997) Pharmacologic Analysis of Drug-Receptor Interaction. Lippincott-Raven, Philadelphia.
49. Kenakin T (2005) New concepts in drug discovery: collateral efficacy and permissive antagonism. Nat Rev Drug Discov 4:919-927.
50. Kikuchi T, Tottori K, Uwahodo Y, Hirose T, Miwa T, Oshiro Y, and Morita S (1995) 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)- quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther 274:329-336.
51. Kilts JD, Connery HS, Arrington EG, Lewis MM, Lawler CP, Oxford GS, O'Malley KL, Todd RD, Blake BL, Nichols DE, et al. (2002) Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs. J Pharmacol Exp Ther 301:1179-1189.
52. Kniazeff J, Bessis AS, Maurel D, Ansanay H, Prezeau L, and Pin JP (2004) Closed state of both binding domains of homodimeric mGlu receptors is required for full activity. Nat Struct Mol Biol 11:706-713.
53. Kobilka BK and Gether U (2002) Use of fluorescence spectroscopy to study conformational changes in the beta 2-adrenoceptor. Methods Enzymol 343:170-182.
54. Kunishima N, Shimada Y, Tsuji Y, Sato T, Yamamoto M, Kumasaka T, Nakanishi S, Jingami H, and Morikawa K (2000) Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor. Nature (Lond) 407:971-977.
55. Kurrasch-Orbaugh DM, Parrish JC, Watts VJ, and Nichols DE (2003a) A complex signaling cascade links the serotonin2A receptor to phospholipase A2 activation: the involvement of MAP kinases. J Neurochem 86:980-991.
56. 2 signaling pathways have different receptor reserves. J Pharmacol Exp Ther 304:229-237.
57. Largent BL, Robichaud AJ, and Miller KJ (2002) Promise and progress of central G protein-coupled receptor modulators for obesity treatment. Ann Rep Med Chem 37:1-10.
58. Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA, Gonzalez AM, Sibley DR, and Mailman RB (1999) Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20:612-627.
59. Lawler CP, Watts VJ, Booth RG, Southerland SB, and Mailman RB (1994) Discrete functional selectivity of drugs: OPC-14597. a selective antagonist for post-synaptic dopamine D2 receptors. Soc Neurosci Abstr, Abstracts 20, 525. Society for Neuroscience, Washington, DC.
60. Lew MJ, Ziogas J, and Christopoulos A (2000) Dynamic mechanisms of non-classical antagonism by competitive AT(1) receptor antagonists. Trends Pharmacol Sci 21:376-381.
61. Liang Y, Fotiadis D, Filipek S, Saperstein DA, Palczewski K, and Engel A (2003) Organization of the G protein-coupled receptors rhodopsin and opsin in native membranes. J Biol Chem 278:21655-21662.
62. Lieberman JA (2004) Dopamine partial agonists: a new class of antipsychotic. CNS Drugs 18:251-267.
63. Lovenberg TW, Brewster WK, Mottola DM, Lee RC, Riggs RM, Nichols DE, Lewis MH, and Mailman RB (1989) Dihydrexidine, a novel selective high potency full dopamine D-1 receptor agonist. Eur J Pharmacol 166:111-113.
64. Mailman RB, Nichols DE, Lewis MM, Blake BL, and Lawler CP (1998) Functional effects of novel dopamine ligands: dihydrexidine and Parkinson's disease as a first step, in Dopamine Receptor Subtypes: From Basic Science to Clinical Application (Jenner P and Demirdemar R eds) pp 64-83, IOS Stockton Press, Washington, DC.
65. Mailman RB, Nichols DE, and Tropsha A (1997) Molecular drug design and dopamine receptors, in The Dopamine Receptors (Neve KA and Neve RL eds) pp 105-133, Humana Press, Totowa, NJ.
66. Miller KJ, Robichaud AJ, and Largent BL (2000) 5-HT2C receptor-mediated activation of IP3 and cGMP in HEK293 cells: evidence for agonist directed trafficking. Soc Neurosci Abstr, Abstract 26, Number 46.6. Society for Neuroscience, Washington, DC.
67. 1 dopamine receptor agonist. J Pharmacol Exp Ther 262:383-393.
68. Mottola DM, Kilts JD, Lewis MM, Connery HS, Walker QD, Jones SR, Booth RG, Hyslop DK, Piercey M, Wightman RM, et al. (2002) Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase. J Pharmacol Exp Ther 301:1166-1178.
69. Mottola DM, Laiter S, Watts VJ, Tropsha A, Wyrick SD, Nichols DE, and Mailman RB (1996) Conformational analysis of D1 dopamine receptor agonists: pharmacophore assessment and receptor mapping. J Med Chem 39:285-296.
70. Newton RA and Elliott JM (1997) Mianserin-induced down-regulation of human 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptors stably expressed in the human neuroblastoma cell line SH-SY5Y. J.Neurochem 69:1031-1038.
71. O'Connor KA and Roth BL (2005) Finding new tricks for old drugs: an efficient route for public-sector drug discovery. Nat Rev Drug Discov 4:1005-1014.
72. Parrish JC, Braden MR, Gundy E, and Nichols DE (2005) Differential phospholipase C activation by phenylalkylamine serotonin 5-HT 2A receptor agonists. J Neurochem 95:1575-1584.
73. 2A receptor activation leads to phospholipase C-dependent release of 2-arachidonoylglycerol (2-AG). J Neurochem 99:1164-1175.
74. 3H]spiroperidol by chronic treatment with the antidepressant amitriptyline. J Pharmacol Exp Ther 215:582-587.
75. Portoghese PS (1965) A new concept on the mode of interaction of narcotic analgesics with receptors. J Med Chem 8:609-616.
76. Prioleau C, Visiers I, Ebersole BJ, Weinstein H, and Sealfon SC (2002) Conserved helix 7 tyrosine acts as a multistate conformational switch in the 5HT2C receptor. Identification of a novel "locked-on" phenotype and double revertant mutations. J Biol Chem 277:36577-36584.
77. Qandil AM, Lewis MM, Jassen A, Leonard SK, Mailman RB, and Nichols DE (2003) Synthesis and pharmacological evaluation of substituted naphth[1,2,3-de]isoquinolines (dinapsoline analogues) as D1 and D2 dopamine receptor ligands. Bioorg Med Chem 11:1451-1464.
78. Rabin RA, Regina M, Doat M, and Winter JC (2002) 5-HT2A receptor-stimulated phosphoinositide hydrolysis in the stimulus effects of hallucinogens. Pharmacol Biochem Behav 72:29-37.
79. Ransohoff RM (2005) Natalizumab and PML. Nat Neurosci 8:1275.
80. Roettger BF, Ghanekar D, Rao R, Toledo C, Yingling J, Pinon D, and Miller LJ (1997) Antagonist-stimulated internalization of the G protein-coupled cholecystokinin receptor. Mol Pharmacol 51:357-362.
81. Rosenthal W, Antaramian A, Gilbert S, and Birnbaumer M (1993) Nephrogenic diabetes insipidus. A V2 vasopressin receptor unable to stimulate adenylyl cyclase. J Biol Chem 268:13030-13033.
82. Roth BL and Chuang DM (1987) Multiple mechanisms of serotonergic signal transduction. Life Sci 41:1051-1064.
83. Roth BL and Ciaranello RD (1991) Chronic mianserin treatment decreases 5-HT2 receptor binding without altering 5-HT2 receptor mRNA levels. Eur J Pharmacol 207:169-172.
84. Roth BL, Sheffler DJ, and Kroeze WK (2004) Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 3:353-359.
85. Ryman-Rasmussen JP, Nichols DE, and Mailman RB (2005) Differential activation of adenylate cyclase and receptor internalization by novel dopamine D1 receptor agonists. Mol Pharmacol 68:1039-1048.
86. Schulz R, Wuster M, and Herz A (1979) Supersensitivity to opioids following the chronic blockade of endorphin action by naloxone. Naunyn-Schmiedeberg's Arch Pharmacol 306:93-96.
87. Shapiro DA, Renock S, Arrington E, Sibley DR, Chiodo LA, Roth BL, and Mailman RB (2003) Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28:1400-1411.
88. Smith HP, Nichols DE, Mailman RB, and Lawler CP (1997) Locomotor inhibition, yawning and vacuous chewing induced by a novel dopamine D2 post-synaptic receptor agonist. Eur J Pharmacol 323:27-36.
89. Sneddon WB, Syme CA, Bisello A, Magyar CE, Rochdi MD, Parent JL, Weinman EJ, bou-Samra AB, and Friedman PA (2003) Activation-independent parathyroid hormone receptor internalization is regulated by NHERF1 (EBP50). J Biol Chem 278:43787-43796.
90. Spedding M, Jay T, Costa e Silva J, and Perret L (2005) A pathophysiological paradigm for the therapy of psychiatric disease. Nat Rev Drug Discov 4:467-476.
91. Stahl SM (2001a) Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, "Goldilocks" actions at dopamine receptors. J Clin Psychiatry 62:841-842.
92. Stahl SM (2001b) Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action. J Clin Psychiatry 62:923-924.
93. Sternini C, Spann M, Anton B, Keith DE Jr, Bunnett NW, von Zastrow M, Evans C, and Brecha NC (1996) Agonist-selective endocytosis of mu opioid receptor by neurons in vivo. Proc Natl Acad Sci USA 93:9241-9246.
94. Stout BD, Clarke WP, and Berg KA (2002) Rapid desensitization of the serotonin(2C) receptor system: effector pathway and agonist dependence. J Pharmacol Exp Ther 302:957-962.
95. Swaminath G, Deupi X, Lee TW, Zhu W, Thian FS, Kobilka TS, and Kobilka B (2005) Probing the beta2 adrenoceptor binding site with catechol reveals differences in binding and activation by agonists and partial agonists. J Biol Chem 280:22165-22171.
96. Swaminath G, Xiang Y, Lee TW, Steenhuis J, Parnot C, and Kobilka BK (2004) Sequential binding of agonists to the beta2 adrenoceptor. Kinetic evidence for intermediate conformational states. J Biol Chem 279:686-691.
97. Tamminga CA and Carlsson A (2002) Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis. Curr Drug Targets CNS Neurol Disord 1:141-147.
98. Tateyama M, Abe H, Nakata H, Saito O, and Kubo Y (2004) Ligand-induced rearrangement of the dimeric metabotropic glutamate receptor 1alpha. Nat Struct Mol Biol 11:637-642.
99. Tran TM, Friedman J, Qunaibi E, Baameur F, Moore RH, and Clark RB (2004) Characterization of agonist stimulation of cAMP-dependent protein kinase and G protein-coupled receptor kinase phosphorylation of the beta2-adrenergic receptor using phosphoserine-specific antibodies. Mol Pharmacol 65:196-206.
100. Trester-Zedlitz M, Burlingame A, Kobilka B, and von ZM (2005) Mass spectrometric analysis of agonist effects on posttranslational modifications of the beta-2 adrenoceptor in mammalian cells. Biochemistry 44:6133-6143.
101. Tsuchiya D, Kunishima N, Kamiya N, Jingami H, and Morikawa K (2002) Structural views of the ligand-binding cores of a metabotropic glutamate receptor complexed with an antagonist and both glutamate and Gd3+. Proc Natl Acad Sci USA 99:2660-2665.
102. 2 receptor-mediated signaling pathways. Neuropsychopharmacology, in press.
103. Van AG, Van RM, Sciot R, Dubois B, Vermeire S, Noman M, Verbeeck J, Geboes K, Robberecht W, and Rutgeerts P (2005) Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 353:362-368.
104. Visiers I, Ballesteros JA, and Weinstein H (2002) Three-dimensional representations of G protein-coupled receptor structures and mechanisms. Methods Enzymol 343:329-371.
105. Visiers I, Hassan SA, and Weinstein H (2001) Differences in conformational properties of the second intracellular loop (IL2) in 5HT(2C) receptors modified by RNA editing can account for G protein coupling efficiency. Protein Eng 14:409-414.
106. Weinstein H (2006) Hallucinogen actions on 5-HT receptors reveal distinct mechanisms of activation and signaling by G protein-coupled receptors. AAPS J 7:E871-E884.
107. Whistler JL, Chuang HH, Chu P, Jan LY, and von Zastrow M (1999) Functional dissociation of mu opioid receptor signaling and endocytosis: implications for the biology of opiate tolerance and addiction. Neuron 23:737-746.
108. Whistler JL, Gerber BO, Meng EC, Baranski TJ, von ZM, and Bourne HR (2002) Constitutive activation and endocytosis of the complement factor 5a receptor: evidence for multiple activated conformations of a G protein-coupled receptor. Traffic 3:866-877.
109. Whistler JL and von Zastrow M (1998) Morphine-activated opioid receptors elude desensitization by beta-arrestin. Proc Natl Acad Sci USA 95:9914-9919.
110. Willins DL, Berry SA, Alsayegh L, Backstrom JR, Sanders-Bush E, Friedman L, and Roth BL (1999) Clozapine and other 5-hydroxytryptamine-2A receptor antagonists alter the subcellular distribution of 5-hydroxytryptamine-2A receptors in vitro and in vivo. Neuroscience 91:599-606.
111. Woolf PJ and Linderman JJ (2000) From the static to the dynamic: three models of signal transduction in G-protein coupled receptors, in Biomedical Applications of Computer Modeling (Christopoulos A ed), pp 87-108, CRC Press, Inc., Boca Raton, FL.
112. Yu Y, Zhang L, Yin X, Sun H, Uhl GR, and Wang JB (1997) Mu opioid receptor phosphorylation, desensitization, and ligand efficacy. J Biol Chem 272:28869-28874.
113. Zhang J, Ferguson SS, Barak LS, Bodduluri SR, Laporte SA, Law PY, and Caron MG (1998) Role for G protein-coupled receptor kinase in agonist-specific regulation of mu-opioid receptor responsiveness. Proc Natl Acad Sci USA 95:7157-7162.